Poland is the largest pharmaceutical market in the Central & Eastern Europe region and the sixth largest in Europe (€ 6.1 billion in market value). With a GDP growth of 3% forecast by the OECD for 2016, there are also clear signs of economic momentum. However, Poland has some of the lowest prices of both innovative and generic drugs in Europe. At the same time, as cost containment measures keep the pressure on other European health authorities to reduce drug reimbursement expenditures, the Polish pharma industry is also struggling to deal with the pressure from its own 2012 Reimbursement Act while reasserting its positioning alongside the Big 5 Germany, France, Spain, Italy and the UK.
Regulating body in pharmacology in Poland is the Central statistical office of Poland. It is engaged in maintaining statistics and makes it possible to study data on the population state of health, incidence, mental health, accidents and injuries, use of the medical and sanitary help, health prevention and life style. In Poland prices for innovative, and generic pharmaceutical products are the lowest in Europe. At the same time, as a measure for control over growth of expenses, Poland holds pressure upon other European bodies of health care.
When including into the reimbursement list medicines, food products of a special purpose and medical products Poland regulatory bodies consider their therapeutic action, safety profile, and total cost of treatment. Pharma products with guaranteed high therapeutic effect and minimal costs get priority when the reimbursed products list is developed by regulatory affairs body. This list is updated every two months. The prices for the reimbursed medicines are fixed and are stipulated with manufacturers.
Regulatory services and regulatory affairs companies help pharmaceutical companies to register pharma products in Eastern European markets.